Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN | NEJM C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of ...

Very pleased to see this RCT of Pegcetacoplan in #C3G and primary #ICMPGN published because it shows evidence of a transformational effect of this treatment in people with a #RareDisease. www.nejm.org/doi/full/10....

#Delphi Consensus on Surrogate Endpoints in #C3G and Primary #ICMPGN

#VisualAbstract by Jade Teakell, MD

www.kireports.org/article/S2468-0249(25)00...

An Exciting Future for C3G/IC-MPGN Treatment (Roundtable) | Docwire News Roundtable panelists share their excitement about the future of therapies for glomerulonephritis, including complement 3 glomerulopathy (C3G) and IC-MPGN.

In the final segment of our roundtable, the panelists share their excitement about recent developments in #nephrology and their visions for the future of #glomerulonephritis therapies. #nephsky #c3g #icmpgn www.docwirenews.com/post/an-exci...

Practical Issues With Implementation of New C3G Therapies (Roundtable) | Docwire News A panel discusses implementing iptacopan and pegcetacoplan to treat complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN).

In the fourth part of our roundtable, the panel delves into the logistics of implementing the new treatments for C3G and IC-MPGN, including safety, vaccination, and adherence. #nephsky #nephrology #c3g #icmpgn www.docwirenews.com/post/practic...

New Therapeutic Options for C3G and IC-MPGN (Roundtable) | Docwire News A panel discusses approved drugs iptacopan for complement 3 glomerulopathy (C3G) and pegcetacoplan for C3G and immune complex membranoproliferative glomerulonephritis (IC-MPGN).

In part 2 of our inaugural roundtable, the panel discusses two recently approved treatments, iptacopan for C3G and pegcetacoplan for C3G and IC-MPGN. #nephrology #nephsky #c3g #icmpgn #glomerulonephritis www.docwirenews.com/post/new-the...

Inside:
- KDIGO & ERA sign new MoU

- #APOL1 Conference Report in @kidneyint.bsky.social

- Take the KDIGO Guideline Survey: kdigo.co/Global-Guide...

- KDIGO at SLANH & ANZSN

- New patient resources incl. a #C3G #ICMPGN program with @medliveofficial.bsky.social , @nordrare.bsky.social & NephCure

🌋The SEISMIC meeting has ignited at our kickoff dinner. Tomorrow we will begin discussions on important issues in the shifting C3G and IC-MPGN landscape.
#GlomerularDisease #C3G #ICMPGN #SEISMIC

Pegcetacoplan Shows Positive Results for Adolescents With C3G and IC-MPGN | Docwire News Pegcetacoplan was found to reduce proteinuria and stabilize eGFR in adolescent patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis.

Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN. #kidneydisease #c3g #icmpgn #pediatrics #nephrology #nephsky #pegcetacoplan www.docwirenews.com/post/pegceta...

Pegcetacoplan Benefits Patients With C3G/IC-MPGN and Nephrotic Proteinuria | Docwire News An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3 glomerulopathy and primary immune complex membranoproliferative and nephrotic range proteinuria.

An analysis confirmed the efficacy and safety of #pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range #proteinuria. #C3G #ICMPGN #kidneydisease #nephrology #nephsky www.docwirenews.com/post/pegceta...

📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease

Thank you to our panel of experts and all the healthcare professionals who joined our #ERA2025 symposium! Valuable insights emerged on evolving treatment paradigms in #C3G and #ICMPGN #kidney_diseases

We start #ERA25 with a poster on unmet needs for patients with #C3G and primary #ICMPGN. Join us today at the poster session at ⏲️ 13:12 CEST in Mozart Symphony N.40 room if you want to learn more about these #complementmediateddiseases #sobi_nephrology #C3inhibition

📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B

Are you travelling to Vienna for #ERA25? So are we!📣 Don’t miss the latest updates in #C3G and primary #ICMPGN #sobi_nephrology/#C3inhibition
🗓️ Program here: shorturl.at/Kpl6T

Index

Join us at #ERA25 in Vienna (4-7 June)! This year's theme is game changers in #nephrology and we look forward to impactful discussions that transform patient outcomes.
📣 Don’t miss the latest updates in #C3G and primary #ICMPGN #sobi_nephrology #C3inhibition

🗓️ Program here: shorturl.at/Kpl6T

Pegcetacoplan for Kidney Transplant Recipients With Recurrent C3G or IC-MPGN | Docwire News The NOBLE trial examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.

NOBLE examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN. #nephsky #nephrology #kidneytransplant #c3g #icmpgn www.docwirenews.com/post/pegceta...

FDA Grants Priority Review to Pegcetacoplan for C3G and IC-MPGN | Docwire News The FDA has granted Priority Review to pegcetacoplan (Empaveli) to treat C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

ICYMI: The FDA has granted priority review to pegcetacoplan for treatment of C3G and IC-MPGN. #kidneydisease #nephrology #c3g #icmpgn #nephsky www.docwirenews.com/post/fda-gra...

Nephrologists face unique challenges in diagnosing and treating #C3G & #ICMPGN. Recent research is changing the landscape.

Learn new diagnostic strategies, review KDIGO guidance, and explore emerging treatments at this 2-part webinar on March 31 at 1pm & 2:30pm ET. 🔗 kdigo.co/Medlive-Nord...

Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy

doi.org/10.1016/j.ek...

#KIRReview #C3GN #ICMPGN

IC-MPGN, a type of #Glomerulonephritis, is a rare #kidneydisease that could be caused by chronic infections like #Hepatitis & #Endocarditis or by chronic inflammation like #Lupus & Rheumatoid #Arthritis. Children can also develop #ICMPGN for unknown reasons

www.rare360.life/post/breakin...

Why Should #RareDisease Patients and Caregivers Care to Participate in #MarketResearch Studies?

www.rare360.life/post/your-in...

#C3G
#C3GN
#ICMPGN
#lupus
#PNH
#rarekidneydisease
#chronickidneydisease
#ourlivesmatter
#nothingaboutuswithoutus
#livingRare